IRIDEX Corporation (Nasdaq: IRIX) announced today that it has expanded its product offering by introducing an optional MicroPulse module in the Company's IQ532 (green) laser system and now provides a complete portfolio of infrared, yellow and green laser systems which can deliver MicroPulse laser treatments.
"Historically laser systems delivering a green wavelength have been our highest selling laser photocoagulators," said Dr. Dominik Beck, IRIDEX President and CEO. "Providing a MicroPulse module in our green laser systems allows the adoption of tissue-sparing therapies by a broader group of ophthalmologists. It is our goal to bring MicroPulse technology to the broadest population of surgeons and patients possible."
Martin A. Mainster, MD, PhD, Professor Emeritus of Ophthalmology of the University of Kansas School of Medicine, commented, "Numerous clinical trials have shown that less destructive and even nondestructive laser phototherapy can achieve therapeutic goals and still preserve visual sensitivity."
Dr. Beck noted that the advances in MicroPulse laser therapy have been made in close collaboration with leading ophthalmologists world-wide.